Scholarly Index
Rachel A. Freedman
Dana-Farber Cancer Institute; 7,280 total citations; 276 total publications; best world rank #34
Dana-Farber Cancer Institute
7,280Total citations
276Total publications
41H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Breast Cancer Treatment Studies | Lifetime | 651 | US 295 | 98.09 |
| Global Cancer Incidence and Screening | Lifetime | 628 | US 334 | 97.18 |
| Economic and Financial Impacts of Cancer | Lifetime | 377 | US 246 | 95.98 |
| Advanced Breast Cancer Therapies | Lifetime | 569 | US 250 | 95.56 |
| Brain Metastases and Treatment | Lifetime | 762 | US 417 | 95.54 |
| Multiple and Secondary Primary Cancers | Lifetime | 951 | US 407 | 91.61 |
| Breast Implant and Reconstruction | Lifetime | 882 | US 425 | 91.72 |
| Male Breast Health Studies | Lifetime | 298 | US 117 | 76.42 |
| Breast Cancer Treatment Studies | 2021-2025 | 124 | US 45 | 98.41 |
| Global Cancer Incidence and Screening | 2021-2025 | 170 | US 66 | 96.42 |
| Cancer Risks and Factors | 2021-2025 | 218 | US 85 | 90.57 |
| Advanced Breast Cancer Therapies | 2021-2025 | 391 | US 143 | 92.89 |
| BRCA gene mutations in cancer | 2021-2025 | 440 | US 206 | 89.37 |
| HER2/EGFR in Cancer Research | 2021-2025 | 554 | US 199 | 91.00 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 268 | US 106 | 83.78 |
| Male Breast Health Studies | 2021-2025 | 34 | US 19 | 81.52 |
| Breast Lesions and Carcinomas | 2021-2025 | 626 | US 186 | 79.24 |